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INTRODUCTION
Peripheral  neuropathy  caused  by  Diabetes  (DM)  was  recognised  only  in  1864  by 
Marchel  de  Calvi.(1)  Till  then it  was  assumed that  diabetes  was  caused by disease  of  the 
nervous system. However,  once the relationship was rightly recognized, much documentary 
evidence  soon  emerged  regarding  the  various  clinical  manifestations  occurring  in  diabetic 
peripheral neuropathy. Thus, the loss of tendon reflexes in the legs was described by Bouchard 
(1887),(2)  similarities  to  tabes  stressed  by  Althaus  (1885)(3),  spontaneous  pain  and 
hyperesthesia  by  Pavy  (1885)(1904)(6)  and  motor  manifestations  by  Bruns  (1890)(6)  and 
Charcot (1890) and cranial nerve involvement by Ogle (1896).(8) While Leyden (1893)(9) and 
Pryce (1893)(10) set out a classification of the different manifestations of the disease, is was 
Rundles11 who in 1945 first drew attention to the autonomic nerve involvement in diabetes. 
Later, scientists turned their interest to the etiopathogenetic mechanisms resulting in peripheral 
neuropathy. This in turn gave impetus to the experimental production of diabetic neuropathy 
(DN) in order to understand the evolution of the disease. Though a large volume of work has 
been  carried  out  in  this  regard  and  many  problems  solved,  many  questions  still  remain 
unanswered. There is a need, therefore, for more comprehensive  studies of the prevalence, 
severity,  natural history, and cause of specific  types of diabetic neuropathy.
AIMS AND OBJECTIVES
1. To assess the incidence of various types of Diabetic Neuropathies
2. To examine the Clinical Profile of each type of Diabetic Neuropathy
3. To study the Neurophysiologic patterns in each type of Diabetic Neuropathy and the 
extent of their clinical correlation.
REVIEW OF LITERATURE
Diabetes mellitus imposes substantial burdens on the nervous system and is the most 
common cause of neuropathy or peripheral nerve damage. Moreover, diabetic neuropathies are 
rising in prevalence with the growing global burden of type II diabetes mellitus. Although this 
review  emphasizes  peripheral  nerve  disorders,  there  is  now recognition  that  diabetes  also 
targets  the  central  nervous  system,  especially  white  matter  (diabetic  leukoencephalopathy).
(24,25) Within the peripheral nervous system alone, however, diabetes renders several types of 
nerve  damage,  including  diffuse  damage  (polyneuropathy)  and  focal  damage 
(mononeuropathy). Both contribute to sensory and motor deficits and both are associated with 
significant disability in patients. In polyneuropathy it is now recognized that impaired glucose 
tolerance, even without overt diabetes mellitus, may be a risk factor.
 The San Antonio Consensus criteria are commonly used to define diabetic neuropathy 
for research purposes.(26) For clinical neuropathy, the guidelines require symptoms and signs, 
or  one  of  these  with  abnormal  testing  (nerve  conduction,  quantitative  sensory  testing,  or 
autonomic  testing).  Subclinical  neuropathy  is  identified  by  abnormal  testing  only.  More 
specific  staging  of  diabetic  polyneuropathy  (DPN)  has  also  been  described  by  Dyck  and 
Dyck(27):  NO, no neuropathy; N1,  asymptomatic neuropathy without (N1a) or with (N1b) 
findings on neurological examination; N2, symptomatic; N3, disabling. Both pathophysiology 
and therapy for diabetic neuropathies remain challenging. There has been a long history of 
failed clinical trials for polyneuropathy, in part related to issues of what was targeted, what was 
being measured, and how well the trial was designed. Despite these problems, there are new 
and  exciting  thoughts  about  how  these  disorders  develop  and  what  avenues  may  offer 
significant hope. Because of the size of the topic, a number of aspects are only covered briefly 
in this review and the bias is  toward emphasizing aspects of its neurobiology. Three excellent 
and comprehensive  texts  addressing diabetic  neuropathy have been published (28,29,30)  in 
addition to recent reviews addressing slightly different points of view, and diagnostic criteria 
have recently been published by the American Diabetes Association.(31)
CLASSIFICATION AND PREVALENCE
Diabetic  neuropathies  comprise  diabetic  polyneuropathy  (DPN),  a  symmetric  diffuse 
disorder that particularly targets sensory neurons with long axons, and focal neuropathies or 
mononeuropathies. The latter include classic entrapment neuropathies that are more common in 
diabetes such as carpal tunnel syndrome (CTS), ulnar neuropathy at the elbow (UNE), meralgia 
paraesthetica (entrapment of the lateral femoral cutaneous nerve of the thigh) at the inguinal 
ligament,  or  peroneal  neuropathy  at  the  fibular  head.  Other  mononeuropathies  much more 
specifically  identified  in  diabetic  patients  include  intercostal  and  abdominal  segmental 
radiculopathies, oculomotor palsies, and lumbosacral radiculoplexus neuropathies. 
Brown and Asbury (32)  subdivided DPN clinically into subtypes,  with the group of 
mixed  motor,  sensory,  and  autonomic  neuropathy  representing  70%  of  patients.  A 
predominantly sensory phenotype was found in 39% that was yet further divided into large-
fiber, small-fiber, or mixed neuropathies. Pure motor DPN or autonomic DPN were uncommon 
(_1% each). In the author’s experience, pure sensory DPN on the basis of clinical evaluation 
alone  (some  have  subclinical  electrophysiological  motor  involvement)  represents  the  large 
majority of patients, particularly early in their course. Some have added a category of an acute 
sensory DPN with rapid onset (likely overlapping with a condition known as “insulin neuritis” 
or neuropathy after the onset  of insulin use),  an association with acute hyperglycemia,  the 
presence of prominent pain, and a shorter overall duration related to control of hyperglycemia. 
The reported prevalence of DPN varies with the type and the intensity with which it is 
sought.  In  the  classic  Diabetes  Control  &  Complications  Trial  (DCCT)  of  diabetic 
complications in intensively rather than conventionally treated patients with type I  diabetes 
mellitus,46 clinical neuropathy was defined as an abnormal clinical neurological examination 
plus  either  abnormal  nerve  conduction  in  at  least  two  peripheral  nerves  or  unequivocally 
abnormal  autonomic-nerve  testing.  In  patients  without  neuropathy  at  baseline,  9.8%  of 
conventional  and  3.1% of  intensively  treatment  patients  had  developed  it  by  5  years.  For 
patients in the secondary intervention cohort with retinopathy at baseline but not neuropathy, 
the rates were 16.1% for conventional and 7.0% for intensive treatment. Overall, when looking 
at a variety of studies (summarized by Shaw et al).(33), type I diabetic prevalence figures vary 
from 13%–17% in hospitalized patients based on symptoms and signs, and 8%–54% with more 
comprehensive batteries in primary care or population-based screening. For type II diabetic 
patients,  similar  figures  run  from 19%–58% in  hospital-based  studies  with  some  ancillary 
testing and 13%–46% in primary care or population-based screening more heavily weighted 
toward testing. 
There are likely significant flaws, however, from relying on hospital-selected data. With 
very comprehensive and extensive batteries of evaluation, such as that applied to the Rochester 
Diabetic Cohort (n _ 380), evidence of DPN was identified in 54% of type I diabetics and 45% 
of type II diabetics. Using the strict criteria of an abnormal neuropathy impairment scale (NIS) 
and  seven  abnormal  laboratory  studies,  21%  of  the  Rochester  diabetic  cohort  had  DPN. 
Symptomatic DPN was identified in a smaller proportion, 13%–15%. In other cohorts, such as 
the Pittsburgh epidemiology of diabetes complications (n _ 400), DPN was identified in 34% of 
type I diabetics, whereas in the San Luis Diabetes Study DPN was present in 26% of type II 
diabetics (n _ 279). In patients with impaired glucose tolerance only, as a precursor of type II 
diabetes,  the  prevalence  figures  have  been  more  controversial.  The  prevalence  of 
cardiovascular  autonomic  neuropathy  detected  by  heart-rate  interval  studies  (including  the 
response to Valsalva’s maneuver, or deep breathing) has ranged from _16%–25% in type I and 
II diabetic patients, with a smaller proportion having symptoms. 
Several studies have suggested that cardiovascular autonomic neuropathy is a risk factor 
for increased mortality.  For gastrointestinal symptoms, prevalence figures are also variable, 
with numbers for constipation or diarrhea ranging between 3% and 35%. Impotence has been 
identified in 23%–57% of type I and II diabetic men, with higher rates with increasing age.(33) 
Overall,  a  population-based  study  from  the  Rochester  diabetic  cohort  (n  _  231  diabetics) 
identified a prevalence of autonomic dysfunction (using a composite scale of laboratory-based 
autonomic tests known as CASS) of 54% in type I diabetics and 73% in type II diabetics, with 
postural hypotension in 8.4% and 7.4%, respectively.  
INDIAN SCENARIO
There is a higher prevalence of DM in India (4.3%)(34) compared with the West (1%–
2%).(35)  Probably  Asian  Indians  are  more  prone  for  insulin  resistance  and cardiovascular 
mortality.(37) The incidence of DN in India is not well known but in a study from South India 
19.1% type II diabetic patients had peripheral neuropathy.(38) DN is one of the commonest 
causes  of  peripheral  neuropathy.  It  accounts  for  hospitalisation  more frequently  than other 
complications of diabetes and also is the most frequent cause of non-traumatic amputation. 
Diabetic  autonomic  neuropathy  accounts  for  silent  myocardial  infarction  and  shortens  the 
lifespan resulting in death in  25%– 50% patients  within 5–10 years  of  autonomic diabetic 
neuropathy.(39,40) According to an estimate, two thirds of diabetic patients have clinical or 
subclinical neuropathy. 
The  diagnosis  of  subclinical  DN  requires  electrodiagnostic  testing  and  quantitative 
sensory  and  autonomic  testing.  All  types  of  diabetic  patients—insulin  dependent  diabetes 
mellitus (IDDM), non-insulin dependent diabetes mellitus (NIDDM), and secondary diabetic 
patients—can develop neuropathy. The prevalence of neuropathy increases with the duration of 
diabetes mellitus. In a study, the incidence of neuropathy increased from 7.5% on admission to 
50% at 25 years follow up.(41) This box gives the classification of DN(42).
CLINICAL CLASSIFICATIONS OF DIABETIC NEUROPATHIES
Symmetric
 Diabetic polyneuropathy
 Painful autonomic neuropathy
 Painful distal neuropathy with weight loss “diabetic Cochexia”
 Insulin neuritis
 Polyneuropathy after ketoacidosis
 Polyneuropathy with glucose impairment
 Chronic inflammatory demyelinating polyneuropathy with diabetes mellitus
Asymmetric
 Radiculoplexoneuropathies
o Lumbosacral
o Thoracic
o Cervical
 Monoeuropathies
 Median neuropathy at wrist
 Ulnar neuropathy at the elbow
 Peroneal neuropathy at the fibular head
 Cranial neuropathy
DISTAL SYMMETRICAL POLYNEUROPATHY (DSPN)
DSPN is the commonest type of DN and probably accounts for 75% of DNs. Many 
physicians incorrectly presume that DSPN is synonymous with DN. It may be sensory or motor 
and  may  involve  small  or  large  fibers,  or  both.  Sensory  impairment  occurs  in  glove  and 
stocking distribution and motor signs are not prominent. 
The sensory symptoms reach up to knee level before the fingers are involved because of 
length  dependent  dying  back  process.  Fiber  dependent  axonopathy  results  in  increased 
predisposition in taller people.(43) DSPN is further classified into large fiber and small fiber 
neuropathy. Large fiber neuropathy is characterized by painless paresthesia with impairment of 
vibration, joint  position, touch and pressure sensations, and loss of ankle reflex. In advanced 
stage, sensory ataxia may occur. Large fiber neuropathy results in slowing of nerve conduction, 
impairment of quality of life, and activities of daily living. Small fiber neuropathy on the other 
hand is  associated with pain,  burning,  and impairment  of pain and temperature  sensations, 
which are often associated with autonomic neuropathy. 
Nerve conduction studies are usually normal but quantitative sensory and autonomic 
tests  are  abnormal.  Small  fiber  neuropathy  results  in  morbidity  and  mortality.  Autonomic 
neuropathy is usually associated with DSPN; but diabetic autonomic neuropathy does not occur 
without sensory motor neuropathy.
PAINFUL DIABETIC NEUROPATHY
About  10%  of  diabetic  patients  experience  persistent  pain.(44)  Pain  in  DN can  be 
spontaneous or stimulus induced, severe or intractable. DN pain is typically worse at night and 
can be described as  burning,  pins and needles,  shooting,  aching,  jabbing,  sharp,  cramping, 
tingling,  cold,  or  allodynia.  Some  patients  develop  predominantly  small  fiber  neuropathy 
manifesting with pain and paresthesia early in the course of diabetes that may be associated 
with insulin therapy (insulin neuritis).(45) It is of less than six  months duration, symptoms are 
aggravated  at  night,  and  manifest  more  in  feet  than  hands.  Sometimes  acute  DN pain  is 
associated  with  weight  loss  and  depression  and  has  been  termed  as  diabetic  neuropathic 
cachexia.(46) This syndrome commonly occurs in men, and can occur at any time in the course 
of both type I and type II diabetes. It is self limiting and responds to symptomatic treatment. In 
these patients  amyloidosis, heavy metal toxicity, Fabry’s disease, and HIV 
CHRONIC PAINFUL DN
Chronic painful DN refers to painful neuropathy occurring over more than six months. 
These patients may develop tolerance to drugs and even get addicted. Neuropathy can develop 
even before the onset of clinically diagnosable diabetes mellitus, which is known as ‘‘impaired 
glucose tolerance neuropathy’’. Symptoms, electrodiagnostic studies, and reduced nerve fiber 
density are consistent  with small fiber neuropathy although the changes are less  prominent 
compared with their florid diabetic counterparts.(47) 
The patients with undiagnosed painful neuropathies therefore should undergo a glucose 
tolerance test.(48) In patients with newly diagnosed diabetes, intermittent pain and paresthesia 
in  distal  lower  limbs  may  suggest  hyperglycaemic  neuropathy,  which  improve  as  the 
hyperglycaemia  is  controlled.  In  DN,  sensory  loss  renders  the  patient  vulnerable  to  foot 
injuries, ulcers, and foot destruction. Foot care therefore is integral part of DN management. 
DIABETIC AUTONOMIC NEUROPATHY
Diabetic  autonomic  neuropathy  affects  various  organs  of  the  body  resulting  in 
cardiovascular, gastrointestinal, urinary, sweating, pupils, and metabolic disturbances. Because 
of diversity of symptoms, autonomic DN often goes unnoticed by both the patient and the 
physician. Autonomic nerve involvement can occur as early as one year after the diagnosis of 
DM. Diabetic autonomic neuropathy usually correlates with severity of somatic neuropathy. It 
ranges  from  subclinical  functional  impairment  of  cardiovascular  reflexes  and  sudomotor 
functions to severe  cardiovascular, gastrointestinal, or genitourinary dysfunction. Orthostatic 
hypotension, resting tachycardia, and heart rate unresponsiveness to respiration are hallmark of 
diabetic  autonomic  neuropathy.  Table  1  summarises  clinical  manifestations  of  autonomic 
diabetic neuropathy.   
CLINICAL MANIFESTATIONS OF AUTONOMIC DIABETIC NEUROPATHY
CARDIOVASCULAR GASTROIN
TESTINAL
GENITOURINARY MISCELLANEOUS
Tachycardia Oesophageal Erectile dysfunction Hypoglycaemia 
Exercise intolerance
Painless myocardial 
infarction
Orthostatic Hypotension
Dysfunciton
Gastroparesis
Diarrhoea
Constipation
Incontinence
Retrograde 
ejaculation 
Cystopathy
Neurogenic bladder
Unawareness 
Miosis 
Argyll Robenson 
Pupil 
Heat intolerance
Sweating disturbance,
Gustatory sweating
                                                                                                 
 Asymmetrical proximal diabetic neuropathy
It  is  also referred to  as  diabetic  amyotrophy but  should  better  be  called as diabetic 
proximal neuropathy.(49) The other examples of proximal DN include thoracic radiculopathy 
and proximal diffuse lower extremity weakness that should be grouped under a single term 
diabetic  polyradiculopathy, as these are diverse manifestations of same phenomena; root or 
proximal nerve involvement.
 The weakness of pelvifemoral muscles occurs abruptly in a stepwise manner in the 
people above 50 years of age. Most of these patients have NIDDM but it is unrelated to the 
severity or duration of diabetes. The patients complain of pain in low back, hip, anterior thigh, 
typically unilateral but may be bilateral. Within days or weeks, the weakness and wasting of 
thigh and leg muscles follows. Knee reflex is reduced or absent. Numbness or paresthesia are 
minor phenomena. Weight loss occurs in more than half the patients. 
Stepwise  progression  occurs  over  months.  Pain  subsides  long  before  the  motor 
symptoms improve, which may take months although mild to moderate  weakness may persist 
indefinitely.  In about 50% patients  with diabetic  proximal neuropathy, DSPN may coexist. 
Nerve biopsy shows multifocal nerve fiber loss suggesting ischaemic injury and perivascular 
infiltrate  suggesting  an  immune  mechanism.(39)  Diabetic  amyotrophy,  which  was  initially 
thought to be attributable to metabolic changes, was later regarded as ischaemic because of 
biopsy changes but now is considered to be attributable to immunological abnormality.(50)This 
has prompted intravenous immunoglobulins (IVIg) and cyclophosphamide therapy, which have 
resulted in rapid recovery.(51,52) In patients with proximal DN, especially if it is bilateral and 
the distal muscles are also involved; electrodiagnostic testing may show demyelinating features 
resembling  chronic  inflammatory  demyelinating  neuropathy  (CIDP).  In  such  patients  apart 
from CIDP, monoclonal gammopathy and vasculitic  neuropathy should also be considered.
(51,53) Biopsy of obturator nerve has shown demyelination, inflammatory cell infiltrate, and 
immunoglobulin deposits in vasanervosa.(54) 
 Cerebrospinal  fluid  protein  may  be  raised  without  lymphocytic  pleocytosis.  It  is 
important  to  differentiate  CIDP  from  lumbosacral  radiculoplexoneuropathy  attributable  to 
ischaemic origin because of different therapeutic options. Diabetic patients are 11 times more 
vulnerable  to  develop CIDP(55)  and they respond to  immunomodulation  by corticosteroid, 
plasma exchange, or IVIg. 
Diabetic  truncal  neuropathy  is  associated  with  pain  and  paresthesia  in  T4–T12 
distribution in chest or abdominal distribution. Bulging of abdominal wall may occur because 
of muscle weakness. It usually occurs in older patients with NIDDM. The onset may be abrupt 
or  gradual  and the  patient  may be confused with an intra-abdominal,  thoracic  disease,   or 
herpes zoster.  The symptoms may generally  persist  for  months before  gradually  subsiding. 
Electromyography may show paraspinal denervation.
Limb neuropathies
There are two major mechanisms of limb neuropathies in diabetics: nerve infarction and 
entrapment.  Nerve  infarctions  are  associated  with  abrupt  onset  pain  followed  by  variable 
weakness and atrophy. As the primary pathology is axonal degeneration, the recovery is slow 
over a period of months. Median, ulnar, and peroneal nerves are most commonly affected.
Mononeuropathy
In  diabetic  patients,  nerve  entrapment  is  commoner  than  nerve  infarction.  The 
entrapment  neuropathies  have  insidious  onset,  have  characteristic  electrodiagnostic  features 
such as conduction block or segmental nerve conduction slowing in the entrapped segment of 
the nerve. Carpal tunnel syndrome is three times more common in diabetic patients than the 
normal population. The other entrapment neuropathies in diabetic patients are ulnar,  radial, 
lateral femoral cutaneous nerve of thigh, peroneal and medial and lateral planter nerves.
Cranial neuropathy
Cranial neuropathy in diabetic patients, most commonly involve the oculomotor nerve 
followed by trochlear and facial nerve in order of frequency. Third nerve palsy with pupillary 
sparing is the hallmark of diabetic oculomotor palsy and is attributed to nerve infarction. The 
pupillary fibres are peripherally located; therefore escape in diabetic oculomotor palsy. 
Multiple neuropathies
Multiple  neuropathies  refer  to  the  involvement  of  two  or  more  nerves.  As  in 
mononeuropathy the onset  is  abrupt in  one nerve and occurs earlier than the other nerves, 
which are involved sequentially or irregularly. Nerve infarctions occur because of occlusion of 
vasa nervosum and should be differentiated from systemic vasculitis.
DIAGNOSIS OF DN
For diagnosis of DN, bedside examination should include assessment of muscle power, 
sensations of pinprick, joint position, touch, and temperature. Vibration test should be done by 
tuning fork of a 128 Hz. For touch sensation mono filament of 1 g is recommended. Sensory 
examination should be performed on hands and feet bilaterally. In old age (.70 years) vibration 
and ankle reflex may be reduced normally and considered abnormal if these are absent rather 
than reduced in a patient with DN. 
Quantitative sensory testing may be used as ancillary test but is not recommended for 
routine clinical practice.(55) The autonomic function tests commonly used in DM are based on 
blood pressure and heart rate response to a series of manoeuvres. Specific tests are used for 
evaluating gastrointestinal, genitourinary, sudomotor function, and peripheral skin blood flow. 
Nerve biopsy may be useful for excluding other  causes of neuropathy. Skin biopsy has been 
used  when all  other  measures  are  negative  in  the  diagnosis  of  small  fibre  neuropathy  for 
quantification of protein gene product 9.(38), which is a panaxonal marker.(56)
 Diabetes as a cause of neuropathy is diagnosed by exclusion of other causes in patients 
who present with painful feet and have impaired glucose tolerance test.(46) Recently confocal 
corneal  microscopy  in  the  assessment  of  diabetic  polyneuropathy  has  been  reported.  In 
confocal microscopy, the cornea is scanned and the images of Bowman’s layer, which contains 
a rich nerve plexus are examined for nerve fibre density, length, and branch density. These 
parameters  are significantly reduced in DN and correlated with the severity  of neuropathy. 
Because of  its noninvasive nature, confocal microscopy may have great potential in assessing 
nerve structure in vivo without need for nerve biopsy.(57) 
The American Academy of Neurology recommends that DN is diagnosed in presence of 
somatic or autonomic neuropathywhen other causes of neuropathy have been excluded.(58) 
About 10% of diabetic patients may have other causes of neuropathy. DN cannot be diagnosed 
without careful examination, because DN may be asymptomatic in a number of patients. At 
least  one  of  each  of  the  five  criteria  is  needed:  symptoms,  signs,  electrodiagnostic  tests, 
quantitative sensory, and autonomic testing.(58) This may be necessary in research protocols. 
However. in clinical practice two of five criteria have been recommended.(59) Underdiagnosis 
or misdiagnosis of DN in clinical practice has been emphasised in the GOAL A1C study in 
which 7000 patients were evaluated and only 38% with mild and 61% with severe neuropathy 
were detected. This study highlighted the importance of education of physician in diagnosing 
DN.(60)
Nerve conduction studies 
Motor nerve conduction, F response, and sensory nerve conduction studies are important 
methods of documentation and follow up of nerve functions in DN. Motor nerve conduction 
studies are affected in a small subset of DN (large fibre neuropathies). Even in large diameter 
fibre neuropathy nerve conduction velocity (NCV) is insensitive for many pathological changes 
known to be associated with DN. The nerve conduction changes are non-specific and key to the 
diagnosis  lies  in  excluding  other  causes  or  those  superimposed  on  DN.  Entrapment 
neuropathies are common in diabetic patients and result in unilateral NCV changes, especially 
across the entrapped segment of the nerve. 
The  commonest  abnormality  in  diabetes  is  reduction  in  the  amplitude  of  motor  or 
sensory  action  potentials  because  of  axonopathy.  Pronounced  slowing  of  NCV  suggests 
demyelinating  neuropathy,  which  is  rarely  associated  with  diabetes;  therefore  pronounced 
slowing of NCV in a diabetic patients should prompt investigations for an alternative diagnosis. 
However,  the likelihood of CIDP occurring in diabetic patients is 11 times higher than the 
normal population.(54)The NCV is gradually diminished in DN, with estimates of a loss of 
about 0.5 m/s/y.(61) In a study on 133 patients with newly diagnosed IDDM followed up for 10 
years it was shown that NCV diminished in six nerves evaluated. 
The maximum deficit  was  3.9 m/s  in  sural  nerve (48.3–44.4 m/s)  whereas  peroneal 
motor NCV was reduced by 3 m/s over same period.(62) A similar slow rate of decline was 
shown in DCC trial. A simple rule is that a 1% fall in Hb1Ac improves the conduction velocity 
by about 1.3 m/s.(61) There is however strong correlation between myelinated fibre density and 
whole sural nerve amplitude.(63)
PATHOGENESIS
The cause of DN though remains unknown but ischaemic and metabolic components are 
implicated. Hyperglycaemia induces rheological changes, which increases endothelial vascular 
resistance  and  reduces  nerve  blood  flow.  Hyperglycaemia  also  causes  depletion  of  nerve 
myoinositol through a competitive uptake mechanism. Moreover, activation of polyol pathway 
in the nerve through enzyme aldose reductase leads to accumulation of sorbitol and fructose in 
the nerve and induces nonenzymatic glycosylation of structural nerve proteins. 
Hyperglycaemia also induces oxidative stress. Activation of protein kinase C has been 
linked to vascular damage in DN. These changes result  in abnormal neuronal,  axonal,  and 
Schwann cell metabolism, which result in impaired axonal transport. Direct measurement of 
glucose,  sorbitol,  and  fructose  in  nerves  of  diabetic  patients  showed  correlation  with  the 
severity of neuropathy. Endoneural hypoxia is produced by increased vascular resistance and 
reduced blood flow in the nerve. Hypoxia leads to further capillary damage, which in turn 
aggravates disturbance in axonal transport and reduced Na-K ATPase activity leading to axonal 
atrophy  and  impairment  of  nerve  conduction.  Unfortunately  the  basic  research  in  DN has 
focused on carbohydrate metabolism; whereas amino acids, electrolytes, and lipid biochemical 
changes, which are associated with DM, have not been investigated with same vigour.
MANAGEMENT OF DIABETIC NEUROPATHY
Disease modification The treatment of DN is aimed at preventing the progression of 
neuropathy  and  providing  symptomatic  relief.  Glycaemic  control  The  relation  between 
hyperglycaemia and development of severity of neuropathy has been shown in retrospective 
and prospective studies. A classic study on 440 diabetic patients who were followed up over 25 
years, showed an increase in clinically detectable DN from 12% at the time of diagnosis of 
diabetes to about 50% after 25 years and those with poorest diabetic control had the highest 
prevalence.7 Significant effect of intensive insulin therapy on prevention of DN were shown in 
DCC trial.(64) 
The  prevalence  rate  for  clinical  or  electrophysiological  evidence  of  neuropathy  was 
reduced by 50% in those treated by intensive therapy during five years. Only 3% of the primary 
prevention cohort treated by intensive insulin therapy showed minimal signs of DN compared 
with 10% of those  treated with conventional  regimen.  In  the  secondary  prevention cohort, 
intensive insulin therapy reduced the prevalence of DN by 50% (7% compared with 16%) in 
intensive and conventional groupsrespectively. The results of DCC trial support the need for 
strict glycaemic control.(63) In the UK prospective diabetes study, control of blood glucose 
was associated with improvement in vibration perception.(65) Reduction of odds ratio for the 
development of autonomic neuropathy to 0.32 was reported in the Steno trial.(66)
Association of vascular risk factors with DN The risk factors for development of DSPN 
in 1172 patients with type I  DM was studied over 7.3 (SD 0.6) years.  Clinical evaluation, 
quantitative  sensory  testing,  autonomic  function  tests,  serum  lipids  and  lipoprotein, 
glycosylated Hb, urinary albumin excretion rate, and serum creatinine were measured in 276 
patients. In this study 23.5% developed neuropathy, which apart from the glycaemic control 
was  related  to  potentially  modifiable  cardiovascular  risk  factors  including  raised  serum 
triglyceride, body mass index, smoking, and hypertension.(67) A stepwise progressive study of 
treatment of type II diabetic patients with hypotensive drugs, angiotensin converting enzyme 
inhibitors,  calcium channel blockers,  hypoglycaemic agents,  aspirin,  hypolipidaemic agents, 
and antioxidants. This study argues for the multifactorial nature of neuropathy and need for 
managing multiple metabolic abnormalities.(66)
MATERIALS AND METHODS
Inclusion criteria
1. Diabetic patients referred to  Neurology O.P.D for symptoms of peripheral neuropathy 
were  assessed  and those with  clinically  demonstrable  Peripheral  Neuropathy  (DPN) 
were screened.
2. Patients who were admitted in General Medical and Neurology ward with symptoms 
related to diabetic neuropathy were also selected for this study.
Exclusion Criteria 
1) Patients with a family history of inherited neuropathies, occupational or environmental 
history of heavy metal exposure, history of lumbar or cervical radiculopathy as well as 
patients using medications which could cause polyneuropathy were excluded. 
2) Patients  with  nutritional  deficiencies,  collagen  vascular  disease,  malignancies,  tabes 
dorsalis, toxin exposure (e.g., alcohol, occupational toxins, vitamin B6, and medications 
known  to  be  associated  with  peripheral  neuropathy),  hypothyroidism,  pernicious 
anemia,  dysproteinemias,  amyloidosis,  AIDS,  spinal  cord  disease,  and  cauda-equina 
syndrome were excluded. 
Methodology                                                                                              
This study was done  over a period of two years - between March 2007 and February 
2009. 156 patients were selected for study, out of the 207 patients screened. The study protocol 
was approved by the Ethics Committee of the Government General Hospital  and all subjects 
gave their informed consent prior to the study.                   
Assessment of neuropathy: Determination  of  whether  a patient had neuropathy was 
based on review of  the medical record, neurologic tests including bed side autonomic function 
tests, nerve conduction (NC) abnormalities. 
Three approaches were used to determine whether a neurologic abnormality was due  to 
diabetes mellitus or  to  another cause: (1)  the patient's  history and the medical record were 
analyzed (2) additional tests were performed  if  needed; and (3) judgments were  made  as to 
whether  the  findings were typical of  diabetic neuropathy.
Systematic questioning, including family history of nondiabetic peripheral nerve disease 
and the presence of toxic, metabolic, mechanical, and vascular causes of nerve disease, was 
conducted.   
All  patients  underwent  tests  for  complete  blood  count  and  routine  serum chemistry 
including lipid profiles as well as tests for thyroid hormones, HbA1C and E.C.G. 
Standardization of examining methods. 
           History  and  physical  examination  were  included  (refer  proforma).  In  the  sensory 
examination ambiguous findings were considered negative.  The response to each test  were 
considered normal, decreased, or absent. The instruments used were  1)  a disposable pin for 
pain evaluation, 2) a cotton tip for light touch, 3) a 128 Hz tuning fork for vibration sensation, 
and  4) finger and toe movements with immobilization of the proximal joint to evaluate joint 
position. The sites examined included the distal toe and distal finger. 
The motor  system was examined manually  for individual muscles with a previously 
used validated grading system. Mechanical devices to evaluate strength may not add precision 
because  they  emphasize  groups  of  muscles  and  because  the  condition  of  the  joints  and 
periarticular tissues frequently are abnormal in diabetes. Muscle testing is of limited value in 
assessing mild diabetic neuropathy. 
Weakness  appears  late  and  usually  only  involves  intrinsic  foot  muscles  and  ankle 
dorsiflexors;  more  proximal  muscles  are  only  involved  in  more  severe  cases  of  diabetic 
polyneuropathy. Reflexes were classified as 1) present and active,  2) present and hypoactive, 
and  3)  absent. Autonomic function tests were done for symptomatic patients. More specific 
staging  of  diabetic  polyneuropathy  (DPN)  described  by  Dyck  and  Dyck(27):  (NO,  no 
neuropathy;  N1,  asymptomatic  neuropathy  without  (N1a)  or  with  (N1b)  findings  on 
neurological examination; N2, symptomatic; N3, disabling) were applied to all patients.
Electrodiagnostic Measures-Standardization 
             The RMS system was used. Recommended filter settings (approximate values) were 
20-3,000  Hz  bandpass  for  sensory  studies,  2-10,000  Hz bandpass  for  motor  studies,  and 
20-10,000 Hz bandpass for needle electromyography. 
Protocol for electrodiagnostic test
A. Motor nerve conduction studies 
1. Unilateral  studies of  ulnar  and median nerve including F waves in the upper 
limb 
2. Unilateral  studies  of peroneal and posterior tibial nerve  including F wave in the 
lower limb 
3.  Measurement of muscle action potential amplitude  and latency at each site of 
stimulation and calculation of segmental conduction velocity 
B. Sensory nerve conduction studies 
1. Unilateral studies of  ulnar and median nerve  in the upper limb 
2. Unilateral studies of either sural or medial plantar nerve in  the lower limb 
3.  Measurement of nerve action potential  amplitude and latency at  each site  of 
stimulation and calculation of segmental conduction velocity 
C. Studies of additional nerves were undertaken to characterize abnormalities based on the 
distribution of clinical symptoms or signs.     
D. Facial  nerve  conduction  was  done  in  all  patients  (even  those  without  clinial 
involvement)            
E. The  normal  values  for  representative  nerve  conduction  values  at  various  sites  of 
stimulation were derived at after analyzing the NC of 30 age matched patients who came 
to Neurology OPD for complaints other than neuropathy.
MOTOR NERVE CONDUCTION
Nerve Distal 
Latency
(ms)
Amplitude 
(mv)
CV (m/s) F-Wave 
Latency (ms)
Median <4.2 >4 >49 <31
Ulnar <3.4 >4.5 >49 <32
Tibial <6.0 >3.5 <40 <56
Peroneal <6.0 >2.2 <40 <56
Facial <1.1 >1.4 - -
SENSORY NERVE CONDUCTION
Nerve Amplitude (uV) CV (m/s)
Median >5 -
Ulnar >5 -
Sural >6 >40
RESULTS
Clinical Characteristics of Study Subjects
The mean age of the diabetics was 53.0 ± 12.4 years. Their ages ranged from 
31–67years. The duration of diabetes varied from newly detected to more than 20 
years with a  mean duration of 7.5 ± 4.2 years. Of the 156 patients 92 were males 
(59.3%) and 64 females (41.2%). 
The highest  proportion among the diabetics  was in the age group of  50–59 
years with a frequency of 34.2%.
Characteristics
(N=156)
Diabetics
Number (Male / Female)
Age (Years)  (Mean, SD)
Duration of Diabetes Mellitus (Years)
Mode of Treatment (%)
         OHA
          Insulin
92/64
53.0 + 12.4 
7.5 + 4.2
59.6%
33.8%
Types of Diabetic Peripheral Neuropathy
Sensorimotor  polyneuropathy  was  the  most  common  form  of  peripheral 
neuropathy, with a frequency of 47.4%, followed by mixed type peripheral neuropathy 
(26.7%) and  Autonomic Neuropathy (31.4%).
Grades of Peripheral Neuropathy
The different stages of neuropathy using the Dyck grading system are shown in Table . 
This  was  analyzed  based  on  gender  among  the  diabetics.  Thirty-eight  subjects—8  male 
diabetics and 7 female diabetics (9.6%)—had stage-0 neuropathy, while 39—21 male and 18 
female—diabetics (25%) had stage 1. There was no significant difference between males and 
females with severity of peripheral neuropathy. 
Grades of diabetic-peripheral neuropathy by gender(27)
Grades                            Male Diabetics                         Female Diabetics                          
Stage N 0                                             8                                                    7 
Stage N 1                                            21                                                  18 
Stage  N2                                            51                                                  34
Stage N 3                                            12                                                    5 
Most of the patients were type II, (88.2%) while 16 were type I (11.8%). The mean 
duration of DM was  7.5 ± 4.2   years. Oral hypoglycemic agents (OHA) were the treatment 
used by 81 patients (59.6%), followed by insulin 46 (33.8%), diet 5 (3.7%) and combined OHG 
and insulin in 4 (2.9%). Poor glycemic control was found in 87 patients (64%) while 49 (36%) 
were well controlled. 
Eigty-nine (57.3%) patients were hypertensive while hyperlipidemia was found in 48 
(30.7%) and a  history  of  smoking in  43 (27.3%).  Normal  NCS were found in  55 patients 
(35%). 
Abnormal NCS were found in 101 patients (65%). Nerve conduction abnormalities in 
symptomatic patients were significantly related to poor glycemic control. Seventy-one (81.6%) 
poorly  controlled  patients  had  abnormal  NCS as  compared  to  16  (18.4%)  well  controlled 
patients (P <0.001). Long duration of DM was also strongly related to abnormalities in NCS, 
the mean duration of DM in patients with NCS abnormalities was 7.4 years as compared to 3.1 
years in those with normal NCS (P <0.001). Abnormal NCS were also significantly associated 
with  insulin  use,  32  (69.6%)  of  those  on  insulin  showed  abnormal  NCS compared  to  14 
(30.4%) who showed normal NCS.                                                                             
There was no significant relation between abnormal NCS and patients age (p0.4), sex 
(p0.7), type of DM (p0.1), hypertension (p0. 5), hyperlipidemia (p0.23) or smoking (p0.13)
SEX DISTRIBUTION
A total of 156 patients fulfilled the criteria were included in the study. There were 
92(59%) males and 64(41%) females among 156 diabetic patients.
TABLE -  1
Total No. of patients 156
Male 92 (59%)
Female 64 (41%)
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AGE AND SEX DISTRIBUTION:
Males predominated in all age groups. Around two thirds of males (85%) were in the 
age group between 40 and 70 years and two-third of females (84%) were in the age group 
between 40 and 70 years. The Table 2 shows age distribution based on sex.
TABLE - 2
AGE AND SEX DISTRIBUTION MALES FEMALES
31 -  40 Years 14(15%
)
10(16%)
41 - 50 Years 24(26%
)
12(19%)
51 -  60 Years 28(30%
)
24(37%)
61 -  70 Years 26(28%
)
18(28%)
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DURATION OF DIABETES
Among the patients studied the duration of diabetes  more than 5 years in 69% male 
patients and 73% of female patients 
TABLE - 3
DURATION OF DIABETES MALES FEMALES
2 TO 3 YEARS 14(15%) 8(13%)
4 TO5 YEARS 24(26%) 20(32%)
6TO 7YEARS 28((30%) 26(40%)
8 TO 9YEARS 12(13%) 10(16%)
>9YEARS 16(17%) 8(13%)
DURATION OF SYMPTOMS
Among the patients studied about two thirds ( 78% of males and 57% females ) had 
diabetic neuropathic symptoms in the duration of 6 months to more than 2 years as shown in 
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table 4. 
TABLE-  4
duration of symptoms MALES FEMALES
<3MONTHS 4(4%) 1(1%)
3 TO 6  MONTHS 10(11%) 6(9%)
6 TO 12 MONTHS 13(14%) 14(22%)
1 TO 2   YEARS 22(24%) 14(22%)
>2 YEARS 43(47%) 29(45%)
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CLINICAL SYMPTOMS
TABLE - 5
CLINICAL SYMPTOMS MALE FEMALE TOTAL
NUMBNESS OF HANDS AND FEET 63(63%) 46(72%) 109(70%)
PINS AND NEEDLES SENSATIONS 33(36%) 42(66%) 86(55%)
BURNING FEET 26(28%) 18(28%) 44(28%)
UNSTEADINESS IN DARKNESS 42(46%) 34(53%) 76(49%)
AUTONOMIC SYMPTOMS
TABLE - 6
AUTONOMIC SYMPTOMS
POSTURAL GIDDINESS 27(17%)
SWEATING DISTURBANCES 13(8%)
BLADDER AND BOWEL DISTURBANCES 12(7%)
ERECTILE DYSFUNCTION 32(20%)
TOTAL 84(54%)
WEAKNESS
TABLE - 7
WEAKNESS PROXIMAL DISTAL
UPPER LIMB 3 36
LOWER LIMB 6 28
BOTH UPPER AND LOWER LIMBS 3 31
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TABLE - 8
SPINOMOTOR SYSTEM
ATROPHY UL LL BOTH
DISTAL 34 26 28
PROXIMAL 4 6 4
WEAKNESS
DISTAL 42 34 31
PROXIMAL 5 8 8
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TABLE - 9
REFLEX LOSS TOTAL
GENERALIZED AREFLEXIA 9 (6%)
ANKLE JERK LOSS 87(56%)
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TABLE - 10
MALES FEMALES TOTAL
GLOVE AND STOCKING TYPE 
SENSORY LOSS
36(39%
)
33(51%) 69(44%)
POSITIVE ROMBERG TEST 36(39%
)
33(51%) 69(44%)
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AUTONOMIC FUNCTIONS
TABLE - 11
AUTONOMIC FUNCTIONS
SWEATING DISTURBANCES AND 
TROPHIC CHANGES
13(8%)
BP AND HEART RATE RESPONSE TO 
POSTURE
12(8%)
HEART RATE RESPONSE TO DEEP 
BREATHING
9(6%)
VALSALVA MANEUVURE 7(4%)
TOTAL 41(26%)
0
13
12
9
7
41
0
5
10
15
20
25
30
35
40
45
SW
EA
TI
NG
 D
IS
TU
RB
AN
CE
S 
AN
D 
TR
OP
HI
C 
CH
AN
GE
S
BP
 A
ND
 H
EA
RT
 R
AT
E 
RE
SP
ON
SE
 T
O 
PO
ST
UR
E
HE
AR
T R
AT
E 
VA
RI
AT
IO
N 
TO
 
TO
 D
EE
P 
BR
EA
TH
IN
G
VA
LS
AL
VA
 M
AN
EU
VU
RE
TO
TA
L
Series1
Series2
Series3
Series4
Series5
Series6
Series7
BLOOD SUGAR
FASTING
TABLE 12.
FASTING MALE FEMALE TOTAL
100 mg TO 150mg 14(15%
)
11(17%) 25(16%)
150mg TO 200mg 53(58%
)
39(61%) 92(59%)
>200mg 25(27%
)
14(22%) 39(25%)
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BLOOD SUGAR
POST-PRANDIAL
TABLE - 13
POSTPRANDIAL MALES FEMALES TOTAL
150mg TO 200mg 6(6%) 7(11%) 13(8%)
200mg TO 250mg 18(19%) 14(22%) 32(20%)
250mg TO 300mg 46(50%) 31(48%) 77(49%)
>300mg 22(24%) 12(19%) 34(22%)
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HbA1C
TABLE - 14
HbA1C 43(28%)
6 TO 7% 13(8%)
7 TO8% 29(19%)
8 TO 9% 11(7%)
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SUMMARY OF  NERVE CONDUCTION STUDIES 
DISTAL MOTOR LATENCY
Nerves
Total 
No. Of 
Patients
Normal Increased No response
Mean ± 
SD Range
Median 156 94 46 (4†) 16 4.0 ± 1.8 3.1- 12.8
Ulnar 156 108 32 (2†) 16 3.8 ± 1.0 2.6-9
Tibial 148 82 47 19 5.6 ± 1.5 3.6-13.7
Peroneal 152 86 46 20 5.5± 1.2 3.9-9.5
Facial 156 147 9 (5†) -
DISTAL MOTOR AMPLITUDE
MOTOR CONDUCTION VELOCITY
Nerves
Total 
No. Of 
Patients
Normal Decreased No response Mean ± SD Range
Median 156 38 102 (32†) 16 2.6 ± 1.8 0.2- 8.8
Ulnar 156 42 98 (30†) 16 3.0 ± 2.1 0.5-9.1
Tibial 148 37 92 19 2.3 ± 1.5 0.3-6.5
Peronea
l
152
37 95 20
1.8 ± 1.3 0.3-7.4
Facial 156 151 5 (1†) -
F WAVES LATENCY
SENSORY AMPLITUDE
Nerves
Total No. 
Of 
Patients
Norma
l Decreased
No 
response
Mean
± SD Range
Median 156 75 66 (11†) 4 12.0 ± 4.2 1.8-20.0
Ulnar 156 86 58 (8†) 4 11.4 ± 3.1 1-15.0
Lower Limb 137 37 84 16 4.5 ± 2.6 1.3-15.7
SENSORY CONDUCTION VELOCITY (SURAL)
Nerves
Total 
No. Of 
Patients
Normal Decreased No response
Mean ± 
SD Range
Median 156 104 36 (3†) 16 48.8 ± 7.1 19.0-59.0
Ulnar 156 108 32 (2†) 16 48.3 ± 8.8 8.9-54.2
Tibial 148 90 39 19 38.4 ±4.0 20.4-43.0
Peronea
l
152 89 43 20 39.9 ± 2.1 23.0-42.0
Nerves
Total 
No. of 
Patients
Normal Decreased No Response
Mean 
+SD Range
Median  156 88 52 (10†) 16 33.5 ± 3.9 25.0-75.0
Ulnar 156 98 42 (12†) 16 33.8 ± 2.3 20-66
Tibial 148 53 76 19 62.5 ± 4.5 34.0-45.2
Peroneal 152 66 40 46 63.2 ± 4.9 50.0-137.0
† PATIENTS WITH NO UPPER LIMB SYMPTOMS 
MOTOR NERVE CONDUCTION
Nerve No. of 
nerves 
studied
No.(%) of patients 
with findings of focal 
demyelination
Conduction
Block
Temporal
Dispersion
Median 156 46 5 2
Ulnar 156 32 3 1
Peroneal 152 46 3 21
Tibial 148 47 1 8
CLINICAL TYPES OF DIABETIC NEUROPATHIES
TYPES OF NEUROPATHIES MALES FEMALES TOTAL
SYMMETRIC SENSORIMOTOR 52(26.9%
)
26(†)
2(††)
42(21.1%)
23(†)
4(††)
94 (48.0%)
49 (31.4%)
6 (3.8%)
PAINFUL DISTAL SESORY 20(12.8%
)
19(†)
17(10.8 %)
15(†)
37(23.6%)
34(21.9%)
DIABETES WITH AIDP 4(2.5%) 1(0.6%) 5(3%)
DIABETES WITH CIDP 6(3.8%) 6(3.8%)
LUMBOSACRAL  RALICULO 
PLEXONEUROPATHY
2(1.3%) 1(0.6%) 3(2%)
MONONEURITIS MULTIPLEX 3(2%) 3(2%)
CRANIAL NEUROPATHIES 5(3%) 3(2%) 8(5%)
†     WITH AUTONOMIC INVOLVEMENT
† †  WITH CARPAL TUNNEL SYNDROME
Nerves
Total No. 
Of 
Patients
Norma
l Increased
No 
response
Mean ± 
SD Range
Lower Limb 137 74 47 16 35.7 ± 4.4 26.0-49.0
FIG 1.
A PATIENT WITH MEDIAN  SENSORY NERVE CONDUCTION
NORMAL 
DIABETIC  
FIG 2.
A  DIABETIC WITH MEDIAN  
NERVE CONDUCTION STUDY SHOWING  
REDUCED “CMAP”  AMPLITUDE
FIG 2.
MEDIAN NERVE F-WAVE STUDY
NORMAL
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DISCUSSION
DN is a common complication of DM and it is encountered in more than one third of 
diabetic patients(81). Pirar et al(82)  had found a five fold increase in the incidence of DN after 
25 years of follow up. Although methods of assessing peripheral nerve function are improving, 
no  single  test  is  indicative  of  nerve  disease.(68)  The  San Antonio  conference  on  diabetic 
neuropathy(69) recommended obtaining ≥1 measure from each of the following categories to 
better  define  and  classify  diabetic  neuropathy:  clinical  symptoms,  clinical  examination, 
electrodiagnostic studies, quantitative sensory testing and autonomic function testing. Likewise 
we in our study have used NCS as an extension of clinical examination.
Discordance between nerve conduction velocity and symptoms and signs of DN has 
been reported before.(83,84) We found that 35% of our patients with symptomatic DN had 
normal NCS, which is higher than that reported by Sangiorgio et al(83) and Fedele et al(84). 
Also nearly 30% of patients who did not have symptoms related to upper limbs showed some 
abnormality in NCS. This discordance between symptoms and NCS means that we can not rely 
on patient’s symptoms for the diagnosis of DN and we need NCS for better assessment and 
diagnosis of DN. 
The various clinical types of PN in this study correlate well with most studies all over 
the world, with sensorimotor polyneuropathy—diagnosed in 48%—being the most common.
(71)                                          
 Symptoms  of  PN manifested  at  a  significantly  lower  age  in  our  study.  This  is  in 
agreement with Vondrova and coworkers in Czech, who found that diabetic polyneuropathy 
manifested at a younger age.(74) The average age of onset was 40 years in males and 42.3 in 
females.
There  were  no  significant  relation  between  Diabetic  neuropathy  and  sex,  BMI, 
hypertension or hyperlipidemia which is in agreement with the findings of Hillson et al(88) and 
Maser et al(89)
The relation between smoking and DN is conflicting, some reports showed significant 
relation(85) while others(16) didn’t find any relation. We found no significant relation between 
Diabetic neuropathy and smoking.                                                                                             
The overall high frequency of diabetic AN in this study (54%) was in keeping with what 
has been seen by other workers. Fernandez-Castaner and colleagues(76) had reported that 53% 
of an unselected series of diabetics had symptoms suggestive of autonomic dysfunction, while 
Thi and coworkers(77) documented that 67.6% of Vietnamese diabetics have cardiac AN. Most 
studies suggest a fairly close association between AN and sensory neuropathy. This was again 
true  in  our  case,  were   all  diabetics  with  AN had  an  associated  somatic  neuropathy  that 
precedes abnormalities of autonomic function (78). 
While no significant relation has been found between age and abnormal NCS, a strong 
relation was found with poor glycemic control, this means that even young patients can develop 
alteration in NCS if they are not well controlled. As the pathogenic mechanisms of Diabetic 
neuropathy  are  not  fully  understood,  there  is  no  satisfactory  and  fundamental  therapy  for 
Diabetic  neuropathy.  Therefore,  further  researches  are  needed  especially  into  pathogenic 
mechanisms in order that satisfactory treatment is achieved. Good glycemic control is essential 
if the risk of diabetic complications is to be minimized(90). 
There was a strong relation between baseline glycated hemoglobin and the loss of tactile 
sensation and temperature sensation (91). Intensive diabetic control had been shown to reduce 
the occurrence of clinical neuropathy by 60% (92,93). Several prospective randomized clinical 
trials have shown the beneficial effect of tight glycemic control on the progression of chronic 
microvascular  complications  of  DM  (94,95).  This  means  that  strenuous  control  of  blood 
glucose is the key in the ultimate prevention of diabetic neuropathy
In our study too prolonged and poorly controlled DM were the most significant factors 
associated with Diabetic neuropathy as has been reported by others (83,84,85,86). A significant 
proportion of patients in our study who were on insulin had severe PN. This relationship may 
have more to do with poor control of diabetes in these patient, rather than insulin usage by 
itself.  Similar to our report Cheng et al(87) had also shown a significant relation between 
insulin use and Diabetic neuropathy. 
Cranial neuropathies are known to occur commonly in diabetics. There are only few 
studies on the frequency of clinically apparent cranial nerve lesions associated with diabetes 
mellitus. Large retrospective series revealed 0.97% incidence of oculomotor and facial nerve 
palsies in diabetic patients over a 25-year period which was 7.5 fold more frequent than in the 
nondiabetic control group (Urban et al., 1999)(96). Urban et al. (l999)(96)  reported that 77.5% 
of their  diabetic  patients demonstrated a significant prolongation of distal  motor latency of 
VIIth  nerve. 
Johnson and Waylonis (1964) (97) stressed the fact that, even though the conduction of 
limb nerves were unaffected, subclinical involvement of the facial nerve was present in a group 
of known diabetics (Johnson et al.,  1964 ; Waylonis et al.,\1964) (97). In our study a total of 
8(5%) patients had clinical evidence of cranial nerve involvement, among which  6 patients had 
facial nerve involvement,2 patients had  painful oculomotor palsy. But on nerve conduction 
studies 14(9%) patients had abnormality in the form of prolonged  DML (9patients) and axonal 
changes(5 patients). Although a few asymptomatic patients in our study did show some NC 
abnormalities, this was not statistically significant. This may be due to the fact that most of the 
polyneuropathy in diabetes being length-related, facial nerve conduction may be less impaired 
than limb nerve conduction.
Several workers have demonstrated subclinical  involvement of nerve fibres in patients 
with diabetes by comparing conduction between patients and normal subjects. These studies 
concerned patients with or without diabetic neuropathy (Lawrence and Locke, 1961; Mulder et 
al., 1961; Skillman et al., 1961; Fagerberg et al., 1963; Mayer, 1963; Gamstorp, 1964; Eeg-
Olofsson and Petersen, 1966)(101,102,103,104) and mixed groups (Gregersen, 1964, 1967). In 
the individual patient, slowing in motor conduction was often borderline in the non-affected 
nerves  of  patients  with  isolated  peripheral  nerve  lesions  (Gilliatt  and  Willison,  1962).
(105,106,107)
In  our  study,  although we did not  include asymptomatic  diabetics,  we were  able  to 
analyze the conduction in clinically unaffected limb (mostly upperlimb). Out of 56 patients 
who did not have upperlimb symptoms 32 patients showed abnormalities in motor conduction 
while 15 patients had additional sensory disturbance. 
Many patients with sensory motor neuropathy (76 patients) showed a prolongation in 
distal motor latency in addition to more than 50% reduction in amplitude, this we assume to be 
due to the loss of myelinated fibres. Also 5 patients with sensory motor neuropathy, in addition 
to  prolongation  in  latency  and  reduction  in  amplitude,  showed  a  significant  slowing  in 
conduction velocity pointing to the possibility of additional focal abnormalities.
  The  slowing  in  the  common  peroneal  nerve  was  the  electrophysiological 
parameter  most  closely  related  to  the  severity  of  the  neuropathy  (P  < 0-001).  In  previous 
studies, the average slowing in motor conduction along the median and ulnar nerves has been 
reported to be as severe as in the common peroneal nerve, both in patients with and without 
clinical signs of neuropathy (Mulder et al., 1961; Lawrence and Locke, 1962; Mayer, 1963; 
Gamstorp, 1964;Gregersen, 1967).(116,117,118,101) 
 In our patients, distal slowing as measured by DML was as pronounced in the upper as 
in the lower extremities, but in the more proximal segments of the nerves (as measured by F 
wave latency) slowing was 1.5 times greater in the lower limb nerves than in the upper. This is 
consistent with the findings of Skillman et al. (1961) (119) and of Johnson (1962)  (124) and 
with the more pronounced clinical involvement of the legs than of the arms. 
The 2 main pathophysiologic mechanisms proposed for diabetic neuropathy are nerve 
ischemia (microangiopathy) and metabolic derangement of nerves. However, DM is one of the 
group  of  autoimmune  disorders,  126,127 and  there  is  growing  evidence  that  immune  and 
inflammatory processes play a role in some of the neuropathies occurring in DM, including 
demyelinating polyneuropathy.128,129 Mitchell et al 7 reported finding major histocompatibility 
class II antigen expression on Schwann cells, similar to that found in I-CIDP, in the nerves of 
patients with diabetic amyotrophy. Younger et al 8 found that upto 60% of sural nerve biopsy 
specimens  from  20  diabetic  patients  with  various  types  of  neuropathy  had 
lymphocyticmicrovasculitis or perivasculitis, and endoneurial T-cell infiltrates, with increased 
expression  of  tumor  necrosis  factor  α  cytokines,  and  components  of  the  membrane  attack 
complex.  Several  studies  have  suggested  that  autoantibodies  directed  against  phospholipid, 
130,131 gangliosides, sulphatide, nerve growth factor, and advanced glycation end products 
may play a role in the pathogenesis of diabetic neuropathy. This probably explains the large 
number of patients in our study showing focal changes in NCS.
Limitation of our study:
1. Potential bias of patient referral. Most of the patients referred to our OPD had a severe 
neuropathy
2. Lack of biopsy correlation. 
CONCLUSIONS
1) Among the different types of Diabetic neuropathy, chronic sensorimotor neuropathy was 
the  commonest,  with a prevalence of  48%. Autonomic neuropathy had a prevalence of 
31.4%.  AN  was  almost  always  associated  with  sensory  neuropathy.  Among  the  focal 
neuropathies CIDP was the commonest                                                                        
2) 65% of patients with clinical neuropathy showed abnormalities on nerve conduction studies 
and the remaining had normal NCS but they had features of small fiber neuropathy with 
autonomic  signs.  Nearly  30%  of  patients  with  no  upper  limb  symptoms  showed 
abnormalities  in NCS. showing a  discordance between symptoms and nerve conduction 
studies
3) Longer duration of DM strongly correlated with abnormalities in NCS, the mean duration of 
7.4 years in patients with NCS abnormalities compared to 3.1 years in those with only lower 
limb NCS changes. 
4) Prolonged poorly controlled diabetes was an important risk factor associated with diabetic 
neuropathy. Aggressive/strict control of blood glucose is the key in the  ultimate prevention 
of diabetic neuropathy
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PROFORMA
INSTITUTE OF NEUROLOGY
MADRAS   MEDICAL COLLEGE, CHENNAI – 3.
Name:                Age/Sex:  
MIN No:                                                   I.P.No   
HISTORY:                                                                                                     Duration of Diabetes 
                                                                 DURATION:
               
                                           Lower Limbs                      Upper Limbs 
                                   RT                  LT           RT                      LT      
Sensory symptoms
Numbness       :                          
Paresthesias                :
Sensory loss :
Touch, Pain, Temperature  
                                 Loss : 
Autonomic symptoms 
Postural Giddiness                : 
sweating disturbances             : 
Bladder and bowel symptoms :  
Erectile dysfunction :
Weakness  Distal :                                                                                            
                   Proximal  :
Atrophy :
Other system involvement :
PAST HISTORY: 
HT /HYPOTHYROIDISM / RA / TRAUMA/  TB / RENAL FAILURE
FAMILY HISTORY:
OCCUPATION:
PERSONAL HISTORY: smoker/alcoholic/substance abuse
SIGNS:   Cranial Nerves
                                      
                                            Lower Limbs                      Upper Limbs 
                                         RT                  LT           RT                      LT      
Spinomotor
Atrophy :
Weakness  Distal                    :                                                                       
                   Proximal  :
Reflexes :
Sensory loss 
Touch, Pain, Temperature       : 
Vibration and JPS :
Romberg’s test :
Autonomic Functions
Sweating and Trophic changes: 
Bp HR Response to posture      : 
HR response to Deep breathing : 
Valsalva maneuver    :
INVESTIGATIONS:
TC 
DC
ESR
Blood sugar
F PP GTT HbA1C ECG OTHERS
INSTITUTE OF NEUROLOGY
MADRAS   MEDICAL COLLEGE, CHENNAI – 3.
NERVE CONDUCTION STUDY 
Name:                Age/Sex: Date:                MIN 
No:                                                         Unit:
MOTOR NERVE CONDUCTION STUDY
Nerve Distal Latency
(ms)
Amplitude 
(mv)
CV (m/s) F-Wave 
Latency (ms)
Median
Ulnar
Tibial
Peroneal
Facial
Sensory Nerve Conduction Study
Nerve Latency Amplitude (uV) CV (m/s)
Median
Ulnar
Sural
CONCLUSION:
Master Chart
MASTER CHART
Age 
(Years)
Sex 
M/F
Duration 
of DM 
(Years)
Duration 
of 
Symptom
s
Distal Motor  Latency Distal Motor Amplitude Nerve conduction velocity
Media
n
Ulna
r
Tibi
al
Peroneal Media
n
Ulnar Tibial Peroneal Media
n
Ulnar Tibial
(2) (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) (15) (16)
38 M 6 2 y N N N N D N N N N N N
61 M 9 2 y N N N I N D N D N N N
63 F 9 4 m N N N N N N N N N N N
51 M 4 2 y I N I N D N D D D N D
63 M 11 2 y I N N N N D D D D N N
42 F 7 2 y NR I NR I NR D NR N NR D NR
65 F 3 4 m N N N N N N N N N N N
62 M 5 7 m I N N N N N D D D N N
43 M 8 6 m I N N N D N D D D N N
34 F 4 4 m I N NR I N N NR N D N NR
54 M 10 3 y NR I NR NR NR D NR NR NR D NR
47 F 6 1y N N I N D D D D N N D
62 F 8 7 m I N N N D D D N D N N
45 M 4 7 m N N N N N N N N N N N
61 F 11 8 m N N N N D N D D N N N
58 F 7 9 m N N N N N D N N N N N
55 M 4 4 m N N I N D N N D N N N
67 M 7 2 y N I N NR D N D NR N D N
40 F 9 2y N N N N N N N N N N N
49 F 5 1 y N N I N D N N N N N D
61 M 2 4 m N N N N D D N D N N N
63 M 8 8 m N N NR I D D D N N N NR
59 M 6 5 m N N N N N N N N N N N
62 M 10 3 m N N I N D D N N N N D
31 F 2 5 m N N N NR D N N NR N N N
N – Normal I – Increased D – Decreased NR – No Response y  - years
m – months 
Pt.No F-Wave Latency Sensory Amplitude
Medi
an
Uln
ar
Tibi
al
Perone
al
Median Ulnar Sural
Sensory 
Conduction 
Velocity 
Sural
Conduction 
Block
Temporal 
Dispertion
Clincal Type of Neuropathy
(18) (19) (20) (21) (22) (23) (24) (25) (26) (27) (28)
1. 1 N N N N N N N D Painful Distal Sensory
2. I N I N N N D N Symmetric Sensorimotor
3. N N N N N N N N - - Painful Distal Sensory
4. I N I N D N D N Symmetric Sensorimotor
5. N N I NR N N NR NR + Symmetric Sensorimotor
6. NR N NR I D N D N Symmetric Sensorimotor
7. N N N N N N N N - - Painful Distal Sensory
8. N N I I N D D N Symmetric Sensorimotor
9. N N I N D N D N Symmetric Sensorimotor
10
.
N N NR N N D D D Symmetric Sensorimotor
11
.
NR I NR NR NR NR NR NR + + CIDP
12
.
N N N N D N D N Symmetric Sensorimotor
13
.
N N I N N D D N Symmetric Sensorimotor
14
.
N N N N N N N N - - Painful Distal Sensory
15
.
N N I I D N NR NR Symmetric Sensorimotor
16
.
I N N NR N D D D + Symmetric Sensorimotor
17
.
N N I N D N D N Symmetric Sensorimotor
18
.
I N N NR D D D N + Symmetric Sensorimotor
19
.
N N N N N N N N - - Painful Distal Sensory
20
.
N N N - N D D N Symmetric Sensorimotor
21
.
N N I NR N N D N + Symmetric Sensorimotor
22
.
I N NR N D D D D Symmetric Sensorimotor
23
.
N N N N N N N N - - Painful Distal Sensory
24
.
I N I I D N D N + Symmetric Sensorimotor
25 N I N NR D N N N Symmetric Sensorimotor
N – Normal I – Increased D – Decreased NR – No Response y  - years
m – months 
Age Sex Duration 
of DM
Duration 
of 
Symptom
s
Distal Motor 
Latency
Distal Motor Amplitude Nerve conduction velocity
Medi
an
Ulnar Tibial Per
one
al
Media
n
Ulnar Tibial Peroneal Median Ulnar Tibial Peroneal
(2) (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) (15) (16)
53 M 4 2 y N N N N D N D N N N N
62 F 6 1 y N N N N D D N D N N N
65 F 7 2 y N N N N N N N N N N N
43 M 3 4 m N N N N N N N N N N N
51 F 6 4 m I N N N N D D D D N N
37 M 6 5 m N N I N D N D N N N N
61 M 9 2 y I N NR N D N NR D D N NR
47 M 5 1 y I I N N D D N N D D N
59 F 4 4 m I N N NR N N N NR D N N
57 M 7 7 m I N I N D N D D D N D
62 M 6 1 y N N N I N N D D N N N
38 F 3 5 m I N N N N N N D D N N
64 M 7 1 y N N N N N N N N N N N
58 M 8 5 m NR N N N NR D D N NR N N
45 F 5 1 y I N I N D N N N N N D
61 M 11 2 y N N NR N N N N N N N NR
39 M 4 11 m N N N N N N N N N N N
50 M 6 1 y N I N N D N D D N N N
58 M 9 2 y N N N N N N N N N N N
52 F 7 5 m N N N N N N N N N N N
45 M 4 4 m N N N I I D N N N N N
62 F 7 4 m N N NR N I D D D N N N
57 F 5 1 y N N N N N N N N N N N
49 M 2 1 m NR I I I NR N D D NR D D
45 F 7 1 y N N N N I D D N N N N
N – Normal I – Increased D – Decreased NR – No Response y  - years
m – months 
F-Wave Latency Sensory Amplitude
Median Ulnar Tibial Peroneal Median Ulnar Sural
Sensory 
Conduction 
Velocity 
Sural
Conductio
n Block
Temporal 
Dispertion
Clincal Type of Neuropathy
(18) (19) (20) (21) (22) (23) (24) (25) (26) (27) (28)
N N I NR D N D D Symmetric Sensorimotor
I I I N N D D N Symmetric Sensorimotor
N N N N N N N N - - Painful Distal Sensory
N N N N N N N N - - Painful Distal Sensory
N I N I D D D N + Symmetric Sensorimotor
I N I N N N NR NR Symmetric Sensorimotor
N I NR NR D D D N + Painful Distal Sensory
I N I N N N D N Symmetric Sensorimotor
N I N NR N D - D Painful Distal Sensory
I N N I D N D N Symmetric Sensorimotor
N N I I N N NR NR + Lumbosacral 
radiculoneuropathy
N I I N N D D D Symmetric Sensorimotor
I N N NR N - D Painful Distal Sensory
NR N I N D D N Symmetric Sensorimotor
N N N NR D N NR D + Painful Distal Sensory
I NR NR N D D D D Symmetric Sensorimotor
N N N NR D N NR NR Symmetric Sensorimotor
I I I I N D D N + Symmetric Sensorimotor
N N N N N N N N - - Painful Distal Sensory
N N N N N N N N - - Painful Distal Sensory
I I I N N D D Symmetric Sensorimotor
N N NR I D D D N Symmetric Sensorimotor
N N N N N N N N - - Painful Distal Sensory
NR I I I NR N N N - + AIDP
I I I NR D N D N Symmetric Sensorimotor
N – Normal I – Increased D – Decreased NR – No Response y  - years
m – months 
Age Sex Duratio
n 
of DM
Duratio
n of 
Sympto
ms
Distal Motor                      Latency Distal Motor Amplitude Nerve conduction velocity
Medi
an
Ulnar Tibial Pero
neal
Faci
al
Med
ian
Uln
ar
Tibial Peroneal Median Ulnar Tibial
(2) (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) (15) (16) (17)
43 M 6 9 m N N N N N N N N N N N N
56 F 7 2 y NR N I N N NR D D D NR N D
57 M 7 1 y N N N N N D N N D N N N
63 F 6 1 y N N N I N D N N D N N N
46 M 3 8 m N N N N I D N D D N N D
57 F 6 1 y I N N I N D D N N D N N
35 M 7 2 y I N N NR N N N N NR D N N
64 F 2 4 m I I N I N D N N N N D N
41 M 8 1 m I I I I N N N D D D D D
47 F 6 1 y N N N N N N N N N N N N
53 M 5 1 y N I N I N D D N N N D N
41 M 12 3 y N N N N N N N N N N N N
37 M 6 6 m NR I N N N NR N D D NR D N
52 F 7 2 y N N N N N N N N N N N N
47 M 4 1 y I I NR NR N N D NR NR D D NR
62 F 3 11 m I N N N N D N D N D N N
57 F 5 6 m I N N I N N D D D D N N
56 M 8 1 y I N I NR N D D N NR N N D
53 F 5 4 m N N N N N N N N N N N N
43 M 4 7 m I I N N N D D D N N D N
35 M 6 5 m N N N N N N N N N N N N
52 M 4 7 m I N I I N D N N D N N D
46 F 7 1 y N N I N N N N N N N N D
49 M 2 4 m N N N N N N N NR D N N N
56 F 4 9 m N N N N N D N N N N N N
N – Normal I – Increased D – Decreased NR – No Response y  - years
m – months 
F-Wave Latency Sensory Amplitude
Media
n
Ulnar Tibial Perone
al
Median Ulnar Sural
Sensory 
Conduction 
Velocity 
Sural
Conducti
on Block
Temporal 
Dispertion
Clincal Type of Neuropathy
(18) (19) (20) (21) (22) (23) (24) (25) (26) (27) (28)
N N N N N N N N - - Painful Distal Sensory
NR I I I D D D N + Symmetric Sensorimotor
N N N NR N N D N Symmetric Sensorimotor
I N I N D D NR NR Symmetric Sensorimotor
N N N N N N D D Cranial neuropathy
I I I N N D D D Symmetric Sensorimotor
N N N NR D N - N + Symmetric Sensorimotor
I I I - N D D N Symmetric Sensorimotor
I I NR I N N N N - + AIDP
N N N N N N N N - - Painful Distal Sensory
I N I I N D NR NR + Symmetric Sensorimotor
N N N N N N N N - - Painful Distal Sensory
NR N N N D D D N Symmetric Sensorimotor
N I I I N D - - Painful Distal Sensory
I I NR NR NR NR NR NR + + CIDP
I N I I N N D N Symmetric Sensorimotor
N NR N N D D D N Symmetric Sensorimotor
I I I NR N N D N Symmetric Sensorimotor
N N N N N N N N - - Painful Distal Sensory
I N I I D D D D Symmetric Sensorimotor
N N N N N N N N - - Painful Distal Sensory
N I I N N D D D Symmetric Sensorimotor
I N I N D N - - Symmetric Sensorimotor
N N N N N D D N Cranial neuropathy
N N I I D NR NR + Symmetric Sensorimotor
N – Normal I – Increased D – Decreased NR – No Response y  - years
m – months 
Age Sex Duration 
of DM
Duration 
of 
Symptom
s
Distal Motor 
Latency
Distal Motor Amplitude Nerve conduction velocity
Medi
an
Ulnar Tibial Perone
al
Media
n
Ulnar Tibial Peroneal Median Ulnar Tibial
(2) (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) (15) (16)
51 M 3 4 m N N N N N N N N N N N
46 M 9 2 y N N N I D N D D N N N
52 F 6 1 y N N I N D D N N N N D
33 M 3 4 m I N I NR N N N NR D D D
59 F 4 11 m N N N N N N N N N N N
41 F 5 9 m N N N N N N N N N N N
58 M 4 9 m N N I N D D N D N N N
61 M 8 2 y N N NR N D N NR N N N NR
53 M 7 1 y I N N N N N N N D N N
42 M 10 1 m I I NR D N D NR D D D
51 F 3 3 m I I N N D D D D D D D
60 M 3 4 m I N I NR N D D NR N N D
61 M 4 5 m N N NR N D D N D N N NR
34 F 5 1 y N N N N N N N N N N N
45 M 7 2 y I N I I N N D D D D D
66 M 10 3 y I I N N N D N N N D D
36 M 4 5 m I N N N D D D N D N N
59 F 2 4 m N NR N I N NR N D N NR N
56 M 9 2 y N N N N D N D D N N D
58 F 6 1 y I N N I N D N N N N N
62 M 4 6 m N N N N N N N N N N N
33 F 5 1 y N N N N N N N N N N N
58 M 6 1 y I I I N N N D D D D D
50 M 7 2 y N N I I D N D D N N D
56 F 7 1 y N N N NR D D N NR N N N
N – Normal I – Increased D – Decreased NR – No Response y  - years
m – months 
F-Wave Latency Sensory Amplitude
Median Ulnar Tibial Peroneal Median Ulnar Sural
Sensory 
Conduction 
Velocity Sural
Conduction 
Block
Temporal 
Dispertion
Clincal Type of Neuropathy
(18) (19) (20) (21) (22) (23) (24) (25) (26) (27) (28)
N N N N N N N N - - Painful Distal Sensory
I I N I D D D D + Symmetric Sensorimotor
N N I N N N D N Symmetric Sensorimotor
I I N NR D D D N Symmetric Sensorimotor
N N N N N N N N - - Painful Distal Sensory
I I I N N D D N + Cranial Neuropathy(Facial-Reduced 
amp)
N N I NR D N NR NR Symmetric Sensorimotor
I N NR N N D D N Symmetric Sensorimotor
NR N I NR N N D D + Symmetric Sensorimotor
I I I NR N N N N - - AIDD
N NR N N D D D N Symmetric Sensorimotor
N I I NR N N - - Painful Distal Sensory
I N NR I D D D D Symmetric Sensorimotor
N N N N N N N N - - Painful Distal Sensory
I I I I D N NR NR + + CIDP
I I - NR N D D D Symmetric Sensorimotor
N N N I D N D N Symmetric Sensorimotor
I NR N N D D D Symmetric Sensorimotor
I N NR NR D D NR NR Mononeuritis Multiplex
N I I I N N D N Symmetric Sensorimotor
N N N N N N N N - - Painful Distal Sensory
I N N N N N N N - - Painful Distal Sensory
N I N I D D - - Mononeuritis Multiplex
I N I N D N D N Symmetric Sensorimotor
I I N NR N D D N Symmetric Sensorimotor
N – Normal I – Increased D – Decreased NR – No Response y  - years
m – months 
Age Sex Duration 
of DM
Duration 
of 
Symptom
s
Distal Motor 
Latency
Distal Motor Amplitude Nerve conduction velocity
Medi
an
Ulnar Tibial Perone
al
Media
n
Ulnar Tibial Perone
al
Medi
an
Ulna
r
Tibia
l
Peroneal
(2) (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) (15) (16)
52 M 2 4m N N I N D D N N N N D
60 F 7 1y N I N I N N N D N D N
36 F 6 1y N N I I D D N D N N D
61 M 4 5m N N N N N N N N N N N
41 M 5 1y I I I NR N D D NR D D D
43 F 4 6m N N - N D NR D D N N N
42 F 2 11m N N N N N N N N N N N
62 M 6 1y NR N I N NR N D N NR N D
55 M 5 4m N N N N D D D D N N N
51 F 7 2y I I - N N N N N D D N
59 M 6 1y I N I NR D D N N N N D
42 M 2 9m N N N N N N N N N N N
64 M 7 1y I N I I D D D D D D
36 M 4 1y I I NR NR N D NR NR D D NR
52 M 9 1y I I I N D N D N D D D
55 F 4 9m I I NR N D N NR N N N NR
54 M 11 3y N N NR NR N N NR NR N   N NR
53 F 3 7m I N N N D N N D N N N
60 M 6 6m N N N N N N N N N N N
48 M 4 2y I N N N D D D D N N N
62 M 7 9m NR I NR N NR N NR D NR NR N
51 M 3 1y N NR N I D NR N N N NR N
32 F 4 2y N N N N D N N N N N N
63 M 6 5m N I NR NR D D NR D N D NR
58 F 6 1y N I N N D N N N N D N
N – Normal I – Increased D – Decreased NR – No Response y  - years
m – months 
F-Wave Latency Sensory Amplitude
Me
dian
Ulnar Tibial Perone
al
Median Ulnar Sural
Sensory 
Conduction 
Velocity 
Sural
Conducti
on Block
Temporal 
Dispertion
Clincal Type of Neuropathy
(18) (19) (20) (21) (22) (23) (24) (25) (26) (27) (28)
I N N NR D D NR NR Symmetric Sensorimotor
N NR N N N N D D Symmetric Sensorimotor
I I - I D D D D + Symmetric Sensorimotor
N N N N N N N N -- -- Painful Distal Symmetric
I N I NR N N N D CIDP
N I I - D D D N Symmetric Sensorimotor
N N N N N N N N -- -- Painful Distal Symmetric
NR I N I N N D N + Symmetric Sensorimotor
N N I NR NR NR NR NR -- -- Mononeuritis Multiplex
I N N N D D D N Symmetric Sensorimotor
I I - NR N N D N Symmetric Sensorimotor
N N N N N N N N -- -- Painful Distal Symmetric
N I - I D D D N Symmetric Sensorimotor
I I NR NR N N NR NR -- -- AIDP
N I N D N D N Symmetric Sensorimotor
I NN NR I D D N N Symmetric Sensorimotor
N N NR NR N NR NR NR -- -- Lumbosacral radiculoneuropathy
I NR N I N N N N Symmetric Sensorimotor
N N - N N N N N Cranial Neuropathy(Facial-Reduced amp)
I N N NR N N D N + Symmetric Sensorimotor
NR I NR I D N N D Symmetric Sensorimotor
I N I I N D N N Symmetric Sensorimotor
N I N NR D N D N Symmetric Sensorimotor
I N NR N N D N D Symmetric Sensorimotor
N I I N D N D N Symmetric Sensorimotor
N – Normal I – Increased D – Decreased NR – No Response y  - years
m – months 
Age Sex Duration 
of DM
Duration 
of 
Symptom
s
Distal Motor 
Latency
Distal Motor Amplitude Nerve conduction velocity
Medi
an
Ulnar Tibial Per
one
al
Media
n
Ulnar Tibial Peroneal Median Ulnar Tibia
l
Peroneal
(2) (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) (15) (16)
59 M 4 4m N N - N D N D D N N -
31 M 2 4m NR N - I NR D N N NR N -
65 F 7 1y N N N N N N N N N N N
49 M 7 7m I I I NR D N D NR D D D
50 F 6 6m N NR N N D NR D N N NR N
56 M 6 1y N N N N N N N N N N N
48 F 7 1y NR N N N N N N N NR N N
46 M 11 1m I N I I N N N N D D D
62 F 3 6m I N N N D N N N N N N
63 F 5 2y N N N N N N N N N N N
38 M 6 1y I N I I N D D D N N N
53 M 12 3y I N N N N N N N N N N
57 F 5 9m I N I N D D N N D N D
62 M 10 2y N N N N N N N N N N N
63 F 6 1y N N N N N N N N N N N
43 M 3 6m NR N I NR N N N NR NR N D
55 F 7 4m N N N N N N N N N N N
38 M 4 1y I I I NR N N D NR D D D
61 F 2 6m N N I N D D N N N N D
63 M 6 4m NR I I N D NR D N NR NR N
53 F 7 1y N N N I D D N N N N N
40 F 6 4m N N N N N N N N N N N
51 F 4 7m NR N I I NR N D D NR N D
64 M 3 6m N N N N D N N D N N N
33 M 2 4m N N I NR D D NR N N N D
N – Normal I – Increased D – Decreased NR – No Response y  - years
m – months 
F-Wave Latency 7mSensory Amplitude
Me
dian
Ulnar Tibial Perone
al
Medi4
man
Ulnar Sural
Sensory 
Conduction 
Velocity 
Sural
Conducti
on Block
Temporal 
Dispertion
Clincal Type of Neuropathy
(18) (19) (20) (21) (22) (23) (24) (25) (26) (27) (28)
I N N N D D D D Symmetric Sensorimotor
NR I - I N N D D Symmetric Sensorimotor
N N N N N N N N -- -- Painful Distal Symmetric
I I I NR NR D NR NR + + CIDP
I NR I I D N D - Symmetric Sensorimotor
N N N N N N N N -- --
NR N - N D D - D Symmetric Sensorimotor
I I I I N N D NR -- -- AIDP
I N I N D D D D Symmetric Sensorimotor
N N N N N N N N -- -- Painful Distal Symmetric
I I I N D N NR NR Symmetric Sensorimotor
N N N N N N N N Cranial Neuropathy(Facial↓ amp)
I I I NN D N N N Symmetric Sensorimotor
N N N N N N N N -- -- Painful Distal Symmetric
N N N N N N N N -- -- Painful Distal Symmetric
NR I I NR N D D N Symmetric Sensorimotor
N N N N N N N N -- -- Painful Distal Symmetric
I I I NR D D D NR + + CIDP
I NR II I N N N N Symmetric Sensorimotor
N N N NR D D D N Symmetric Sensorimotor
I I I I N N - - Symmetric Sensorimotor
N N N N N N N N -- -- Painful Distal Symmetric
N N I I N N D NR -- -- Lumbosacral radiculoneuropathy
N I - N D D D N Symmetric Sensorimotor
I N NR D NR N N Symmetric Sensorimotor
N N I NR N D D N Symmetric Sensorimotor
N – Normal I – Increased D – Decreased NR – No Response y  - years
m – months 
Pt.No. Age Sex Duratio
n 
of DM
Duration 
of 
Symptoms
Distal Motor 
Latency
Distal Motor Amplitude Nerve conduction velocity
Medi
an
Ulnar Tibial Pero
neal
Medi
an
Ulnar Tibia
l
Perone
al
Medi
an
(1) (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) (13) (14)
151 61 M 3 7m N NR N I D NR N N N
152 39 F 5 4m N N N N N N N N N
153 62 M 5 1y N N N N D D D N N
154 34 M 7 9m N NR N N D NR N D N
155 64 M 2 4m N N N N N N N N N
156 49 F 6 1y I N N N D N N D D
Pt.No F-Wave Latency Sensory Amplitude
Me
dian
Ulnar Tibial Perone
al
Median Ulnar Sural
Sensory 
Conduction 
Velocity 
Sural
Conducti
on Block
Temporal 
Dispertion
Clincal Type of Neuropathy
(18) (19) (20) (21) (22) (23) (24) (25) (26) (27)
151 N NR I N D NR D D Symmetric Sensorimotor
152 N N N N N N N N -- -- Painful Distal Symmetric
153 I N N I D N D D Symmetric Sensorimotor
154 N NR I NR N D D D Symmetric Sensorimotor
155 I N N N N N N N Cranial Neuropathy-Facial 
156 N N N NR D N D D Symmetric Sensorimotor
N – Normal I – Increased D – Decreased NR – No Response y  - years
m – months 
